美罗培南在重症肺炎患儿临床治疗中的应用研究

Clinical application study of meropenem in the treatment of severe pneumonia in children

目的探讨重症肺炎患儿应用美罗培南治疗的临床效果。方法选择2020年1月—2022年1月本院收治并确诊的80例重症肺炎患儿,按照随机数字表法将其分为对照组与观察组,每组各40例。对照组应用头孢哌酮舒巴坦治疗,观察组在对照组基础上联合美罗培南治疗。比较两组临床疗效,血清降钙素原(PCT)、白细胞介素-13(IL-13)、过氧化脂质(LPO)、超氧化物歧化酶(SOD)水平及血气分析指标。结果观察组治疗有效率高于对照组,两组比较差异有统计学意义(χ^(2)=7.813,P<0.05);观察组治疗后PCT、IL-13、LPO水平均低于对照组,SOD水平高于对照组,两组比较差异均有统计学意义(t=8.729、10.766、11.695、8.780,均P<0.05);观察组治疗后动脉血氧分压(PaO_(2))、动脉血氧饱和度(SaO_(2))均高于对照组,动脉血二氧化碳分压(PaCO_(2))低于对照组,两组比较差异均有统计学意义(t=7.783、6.340、9.506,均P<0.05)。结论对重症肺炎患儿应用头孢哌酮舒巴坦联合美罗培南治疗,能良好地改善患儿病情及相关指标。

Objective To investigate the clinical effect of meropenem in the treatment of children with severe pneumonia.Methods A total of80 children admitted to our hospital and diagnosed with severe pneumonia from January 2020 to January 2022 were selected and randomly divided into a control group and an observation group,with 40 children in each group.The control group was treated with cefoperazone sulbactam,while the observation group received a combination of cefoperazone sulbactam and meropenem.The clinical efficacy,levels of serum procalcitonin(PCT),interleukin-13(IL-13),lipid peroxidation(LPO),superoxide dismutase(SOD),and blood gas analysis indicators were compared between the two groups.Results The effective rate of treatment in the observation group was higher than that in the control group,with a statistically significant difference(χ^(2)=7.813,P<0.05).After treatment,the levels of PCT,IL-13,and LPO in the observation group were lower,while the level of SOD was higher compared to the control group,with significant differences(t=8.729,10.766,11.695,8.780,all P<0.05).The levels of arterial oxygen pressure(PaO_2)and arterial oxygen saturation(SaO_2)in the observation group were higher,and the level of arterial carbon dioxide pressure(PaCO_2)was lower than that in the control group,with significant differences(t=7.783,6.340,9.506,all P<0.05).Conclusion The combined treatment of cefoperazone sulbactam and meropenem in children with severe pneumonia can effectively improve the clinical condition and related biomarkers of children with severe pneumonia.